{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:49:26Z","timestamp":1788983366162,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.psychres.2026.117134","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:53:55Z","timestamp":1774972435000},"page":"117134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Sertraline blood concentrations and clinical efficacy in depression: a retrospective, exploratory determination of optimal therapeutic range"],"prefix":"10.1016","volume":"361","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4452-894X","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Tapia-Alzuguren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2349-3631","authenticated-orcid":false,"given":"Covadonga","family":"Canga-Espina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-9635","authenticated-orcid":false,"given":"Patricio","family":"Molero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3810-6025","authenticated-orcid":false,"given":"Azucena","family":"Aldaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2026.117134_bib0001","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","article-title":"Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy","volume":"37","author":"Alderman","year":"1998","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117134_bib0002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/cap.2006.16.117","article-title":"Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents","volume":"16","author":"Alderman","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117134_bib0003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2026.117134_bib0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2026.117134_bib0005","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/cts.13347","article-title":"Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population","volume":"15","author":"Br\u00e5ten","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.psychres.2026.117134_bib0006","unstructured":"Cabello, M., Ayuso-Mateos, J., 2020. Depresi\u00f3n y Suicidio, 2020. Documento Estrat\u00e9gico Para La Promoci\u00f3n de la Salud Mental. Madrid."},{"key":"10.1016\/j.psychres.2026.117134_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050565","article-title":"A focus on abuse\/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIs): analysis of both the European EMA and the US FAERS pharmacovigilance databases","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.psychres.2026.117134_bib0008","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2026.117134_bib0009","first-page":"1","article-title":"Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy","volume":"21","author":"Furukawa","year":"2018","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.psychres.2026.117134_bib0010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.psychres.2026.117134_bib0011","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1037\/amp0000904","article-title":"Summary of the clinical practice guideline for the treatment of depression across three age cohorts","volume":"77","year":"2022","journal-title":"Am. Psychol."},{"key":"10.1016\/j.psychres.2026.117134_bib0012","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/clinchem\/40.3.498","article-title":"Therapeutic monitoring of sertraline","volume":"40","author":"Gupta","year":"1994","journal-title":"Clin. Chem."},{"key":"10.1016\/j.psychres.2026.117134_bib0013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FTD.0b013e3182885d9d","article-title":"Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram","volume":"35","author":"Haji","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2026.117134_bib0014","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FTD.0000000000001264","article-title":"How to determine a therapeutic reference range for a psychotropic drug systematically? Recommendations of the TDM task force of the AGNP","volume":"47","author":"Hart","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2026.117134_bib0015","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00228-021-03122-z","article-title":"Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low","volume":"77","author":"Heinonen","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2026.117134_bib0016","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2026.117134_bib0017","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges","volume":"41","author":"Hiemke","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2026.117134_bib0018","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2026.117134_bib0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2026.117134_bib0020","series-title":"Global Burden of Disease 2021: Findings from the GBD 2021 Study","year":"2024"},{"key":"10.1016\/j.psychres.2026.117134_bib0022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.298","article-title":"Therapeutic drug monitoring: a patient management tool for precision medicine","volume":"99","author":"Jang","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2026.117134_bib0023","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117134_bib0024","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1034\/j.1600-0447.2000.101005354.x","article-title":"Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients","volume":"101","author":"Lundmark","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2026.117134_bib0025","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2026.117134_bib0026","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.502","article-title":"Long-term efficacy and therapeutic drug monitoring of sertraline in major depression","volume":"18","author":"Mauri","year":"2003","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117134_bib0027","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0278-5846(01)00314-1","article-title":"Clinical outcome and tolerability of sertraline in major depression a study with plasma levels","volume":"26","author":"Mauri","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117134_bib0028","series-title":"Kaplan and Sadock\u2019s Comprehensive Textbook of Psychiatry","first-page":"1614","article-title":"Mood disorders: epidemiology","author":"Merikangas","year":"2017"},{"key":"10.1016\/j.psychres.2026.117134_bib0029","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jat\/22.6.545","article-title":"Fatal multiple drug intoxication following acute sertraline use","volume":"22","author":"Milner","year":"1998","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.psychres.2026.117134_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325335","article-title":"The PREDEP-SERT study protocol: a 6-month follow-up cohort study of predictors of effectiveness, tolerability and safety of sertraline for depression using therapeutic drug monitoring","volume":"20","author":"Molero","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2026.117134_bib0032","first-page":"42","article-title":"Consensus statement on the benefit to the community of ESEMeD (European study of the epidemiology of mental disorders) survey data on depression and anxiety","volume":"68","author":"Nutt","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117134_bib0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s42358-021-00214-3","article-title":"Depression is associated with increased disease activity and higher disability in a large Italian cohort of patients with rheumatoid arthritis","volume":"61","author":"Pezzato","year":"2021","journal-title":"Adv. Rheumatol."},{"key":"10.1016\/j.psychres.2026.117134_bib0034","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.pra.0000445247.54048.68","article-title":"Therapeutic drug monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don\u2019t work","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.psychres.2026.117134_bib0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2026.117134_bib0036","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/hup.599","article-title":"Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression","volume":"19","author":"Reis","year":"2004","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117134_bib0037","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcpt.12938","article-title":"Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers","volume":"122","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.psychres.2026.117134_bib0038","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FTD.0b013e31827a1aad","article-title":"The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study","volume":"35","author":"Taurines","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2026.117134_bib0039","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00228-023-03611-3","article-title":"Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: an observational study of 34,777 individuals","volume":"80","author":"Tveit","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2026.117134_bib0040","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-012-0952-2","article-title":"Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions","volume":"120","author":"Unterecker","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.psychres.2026.117134_bib0041","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FTD.0b013e318241dce0","article-title":"Serum concentrations of antidepressants in the elderly","volume":"34","author":"Waade","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2026.117134_bib0021","unstructured":"Instituto Nacional de Estad\u00edstica (INE), 2021. Mental health during the pandemic. Madrid: INE. Available at: https:\/\/www.ine.es\/ss\/Satellite?L=es_ES&c=INECifrasINE_C&cid=1259953225445&p=1254735116567&pagename=ProductosYServicios%2FINECifrasINE_C%2FPYSDetalleCifrasINE (accessed 8 January 2025)."},{"key":"10.1016\/j.psychres.2026.117134_bib0031","unstructured":"National Institute for Health and Care Excellence (NICE), 2022. Depression in adults: treatment and management (NG222). London: NICE. Available at: https:\/\/www.nice.org.uk\/guidance\/ng222 (accessed 8 January 2025)."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126001952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126001952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:03:21Z","timestamp":1782565401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126001952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"alternative-id":["S0165178126001952"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117134","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sertraline blood concentrations and clinical efficacy in depression: a retrospective, exploratory determination of optimal therapeutic range","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117134"}}